SCHEMBL5765079

SCHEMBL5765079

Cc1nc(Cc2cc(F)cc(F)c2)sc1C1CCNCC1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.38
GPR52 Q9Y2T5 3/20 0.35
NOS2 P35228 1/20 0.35
CDK9 P50750 2/20 0.35
PLAT P00750 2/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
CCNT1 O60563 1/20 0.34
GABRA1 P14867 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
TNKS O95271 2/20 0.33
PARP1 P09874 2/20 0.33
KCNH2 Q12809 2/20 0.33
TNKS2 Q9H2K2 2/20 0.33
CHRM4 P08173 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5765101 0.88 HTR6 (0.50) HTR6GPR52CDK9CCNT1GABRA1
SCHEMBL5763769 0.87 PLAT (0.41) HTR6PLATMKNK1MKNK2GABRA1
SCHEMBL5764687 0.86 CCR5 (0.38) HTR6NOS2CDK9PLATCCNT1
SCHEMBL5762289 0.84 HTR6 (0.38) HTR6GPR52PLATGABRA1GABRG2
SCHEMBL5762754 0.84 HTR6 (0.47) HTR6CDK9CCNT1GABRA1GABRG2
SCHEMBL5762609 0.81 GABRA1 (0.50) PLATGABRA1GABRG2GABRB3MEN1
SCHEMBL5764662 0.81 HTR2C (0.39) HTR6PLATGABRA1GABRG2GABRB3
SCHEMBL5766631 0.80 HTR6 (0.50) HTR6CDK9MKNK1MKNK2CCNT1
SCHEMBL5766073 0.80 HTR6 (0.40) HTR6PLATGABRA1GABRG2GABRB3
Hydrochloric Acid SCHEMBL5765809 0.80 GABRA1 (0.49) PLATGABRA1GABRG2GABRB3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192133-B1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-6538002-B1 In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3. as antiinflammatory agents MERCK & CO., INC. 2003-03-25 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
US-6432981-B1 BLOCKS HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM ENTERING CELLS; AUTOIMMUNE DISEASES; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS MERCK & CO., INC. 2002-08-13 US disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 HTR6 1057/4885GPR52 217/4885NOS2 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.